Literature DB >> 25394972

[Novel molecular aspects of chordomas].

S Scheil-Bertram1.   

Abstract

Chordomas are rare and slowly growing malignant bone tumors which mostly occur in adults. These bone tumors are characterized by epithelial and mesenchymal aspects. It is suggested that they arise from remnants of the notochord because they are found along the axial skeleton (e.g. clival, spinal and sacrococcygeal locations). It appears that cytogenetic aberrations are not randomly found in this tumor group. Loss of chromosomal material (e.g. 1p, 3p, 10q, 13q and 14q) is more frequently found than gain of material (e.g. 7q, especially 7q33). Several studies demonstrated brachyury expression (T; 6q27) as a possible candidate gene in the oncogenesis of chordomas (e.g. knock down in the chordoma cell line U-CH1). So far therapy consists of complete resection and irradiation, e.g. with carbon ions. Targeting therapy is not yet established in routine protocols but phase II studies with tyrosine kinase inhibitors have shown partial response of tumors and, in some studies stabilization of the disease has been described.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25394972     DOI: 10.1007/s00292-014-1986-z

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  29 in total

Review 1.  [Chordoma].

Authors:  B George; D Bresson; S Bouazza; S Froelich; E Mandonnet; S Hamdi; M Orabi; M Polivka; A Cazorla; H Adle-Biassette; J-P Guichard; M Duet; E Gayat; F Vallée; C-H Canova; F Riet; S Bolle; V Calugaru; R Dendale; J-J Mazeron; L Feuvret; E Boissier; S Vignot; S Puget; C Sainte-Rose; K Beccaria
Journal:  Neurochirurgie       Date:  2014-05-23       Impact factor: 1.553

2.  Characterization of T gene sequence variants and germline duplications in familial and sporadic chordoma.

Authors:  Michael J Kelley; Jianxin Shi; Bari Ballew; Paula L Hyland; Wen-Qing Li; Melissa Rotunno; David A Alcorta; Norbert J Liebsch; Jason Mitchell; Sara Bass; David Roberson; Joseph Boland; Michael Cullen; Ji He; Laurie Burdette; Meredith Yeager; Stephen J Chanock; Dilys M Parry; Alisa M Goldstein; Xiaohong R Yang
Journal:  Hum Genet       Date:  2014-07-04       Impact factor: 4.132

3.  Durable stabilization of three chordoma cases by bevacizumab and erlotinib.

Authors:  T Asklund; M Sandström; S Shahidi; K Riklund; R Henriksson
Journal:  Acta Oncol       Date:  2014-01-23       Impact factor: 4.089

4.  The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival.

Authors:  Yunping Hu; Akiva Mintz; Sagar R Shah; Alfredo Quinones-Hinojosa; Wesley Hsu
Journal:  Carcinogenesis       Date:  2014-01-20       Impact factor: 4.944

5.  The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.

Authors:  Asem Shalaby; Nadège Presneau; Hongtao Ye; Dina Halai; Fitim Berisha; Bernadine Idowu; Andreas Leithner; Bernadette Liegl; Timothy R W Briggs; Krisztian Bacsi; Lars-Gunnar Kindblom; Nicholas Athanasou; Maria Fernanda Amary; Pancras C W Hogendoorn; Roberto Tirabosco; Adrienne M Flanagan
Journal:  J Pathol       Date:  2010-12-10       Impact factor: 7.996

6.  Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome.

Authors:  Carolina Vieira de Castro; Gustavo Guimaraes; Samuel Aguiar; Ademar Lopes; Glauco Baiocchi; Isabela Werneck da Cunha; Antonio Hugo Jose Froes Marques Campos; Fernando Augusto Soares; Maria Dirlei Begnami
Journal:  Hum Pathol       Date:  2013-04-22       Impact factor: 3.466

7.  Expression of PDGFR-α, EGFR and c-MET in spinal chordoma: a series of 52 patients.

Authors:  Reza Akhavan-Sigari; Michael Robert Gaab; Veit Rohde; Mehdi Abili; Helmut Ostertag
Journal:  Anticancer Res       Date:  2014-02       Impact factor: 2.480

8.  Expression of hepatocyte growth factor and c-MET in skull base chordoma.

Authors:  Takahiko Naka; Doerthe Kuester; Carsten Boltze; Stefanie Scheil-Bertram; Amir Samii; Christian Herold; Helmut Ostertag; Sabine Krueger; Albert Roessner
Journal:  Cancer       Date:  2008-01-01       Impact factor: 6.860

9.  Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1.

Authors:  Edwin Choy; Laura E MacConaill; Gregory M Cote; Long P Le; Jacson K Shen; Gunnlaugur P Nielsen; Anthony J Iafrate; Levi A Garraway; Francis J Hornicek; Zhenfeng Duan
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

10.  Erlotinib inhibits growth of a patient-derived chordoma xenograft.

Authors:  I-Mei Siu; Jacob Ruzevick; Qi Zhao; Nick Connis; Yuchen Jiao; Chetan Bettegowda; Xuewei Xia; Peter C Burger; Christine L Hann; Gary L Gallia
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.